Radiation-induced coronary artery disease during immune checkpoint inhibitor therapy: a case report
Abstract
Radiation-induced coronary artery disease (RICAD) poses a serious concern for cancer patients post radiotherapy, typically emerging after over a decade. Immune checkpoint inhibitors (ICIs), known for cardiotoxicity, are increasingly recognized for causing cardiovascular complications. Here we report the case of a 63-year-old man with metastatic lung cancer who developed coronary artery disease during his third-line therapy with an ICI (nivolumab) and an antiangiogenic agent (bevacizumab), 3 years post chest radiotherapy. Angiography revealed relatively isolated stenosis in the left main coronary artery ostium, consistent with the radiotherapy site, with no other risk factors, suggesting RICAD. The potential for ICIs to accelerate RICAD development should be considered and necessitates careful surveillance in patients receiving both radiotherapy and ICIs.
Plain language summary
Sometimes cancer patients receive a type of treatment called radiotherapy, which uses high-energy beams to target the cancer. This treatment is very helpful, but when applied to the chest, it can cause problems in the blood vessels of the heart many years later, a condition called radiation-induced heart disease. This report is about a 63-year-old man who developed this heart problem much sooner than usual, just 3 years after receiving radiation treatment for lung cancer. Alongside radiotherapy, he also received two advanced kinds of cancer treatments. One helped his immune system to better identify and fight the cancer, and the other worked to stop the cancer from getting the blood supply it needs to grow. Our report suggests that these new treatments may interact with radiotherapy in a way that causes heart problems more quickly. This is especially important to consider in patients without previous heart problems. Our findings remind doctors to closely monitor the heart health of patients receiving these treatments and point to the need for more research into how these treatments may affect the heart when used together.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . California chiropractors. An epidemiological study of causes of death among them and other characteristics. Calif. Med. 101(5), 341–347 (1964).
- 2. . Radiation-induced heart disease: a practical guide to diagnosis and management. Cleve. Clin. J. Med. 83(12), 914–922 (2016).
- 3. . Experimental radiation-induced heart disease. I. Light microscopic studies. Am. J. Pathol. 59(2), 299–316 (1970).
- 4. . Radiation-induced cardiac dysfunction: practical implications. Kardiol. Pol. 80(3), 256–265 (2022).
- 5. . Dosimetric comparison of the heart and left anterior descending artery in patients with left breast cancer treated with three-dimensional conformal and intensity-modulated radiotherapy. Cureus 14(1), e21108 (2022).
- 6. . Coronary artery disease and breast radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 86(5), 816–818 (2013).
- 7. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368(11), 987–998 (2013). •• These publications furnish a detailed perspective for cardio-oncology and cardiology professionals, framing the management challenges and strategies against the backdrop of a modern understanding of radiation therapy’s impact on cardiac health. They underscore the need to navigate patient care with a nuanced appreciation of the potential or actual cardiac complications arising from such treatments.
- 8. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 26(9), 1013–1032 (2013).
- 9. Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 110(5), 1473–1479 (2021). •• These publications presented the correlation of left anterior descending coronary artery dose and the risk of major adverse cardiac events, serving as the landmarks in cardio-oncology for lung cancer radiation therapy.
- 10. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J. Am. Coll. Cardiol. 73(23), 2976–2987 (2019).
- 11. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J. Clin. Oncol. 34(3), 235–43 (2016).
- 12. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med. 175(6), 1007–1017 (2015).
- 13. . Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin. Proc. 91(1), 81–83 (2016).
- 14. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol. 7(2), 206–219 (2021). •• These publications presented the correlation of left anterior descending coronary artery dose and the risk of major adverse cardiac events, serving as the landmarks in cardio-oncology for lung cancer radiation therapy.
- 15. . Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target. Ther. 7(1), 258 (2022).
- 16. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J. Thorac. Oncol. 13(4), 510–520 (2018).
- 17. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother. Oncol. 190, 110005 (2024).
- 18. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. Cardiovasc. Imaging 23(10), e333–e465 (2022).
- 19. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. JCO 35, 893–911 (2017).
- 20. . Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 19(9), e447–e458 (2018).
- 21. . Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J. Am. Coll. Cardiol. 70(20), 2536–2551 (2017).
- 22. . Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin. Interv. Cardiol. 3(3–4), 163–172 (1998).
- 23. . Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol. 61(23), 2319–2328 (2013).
- 24. Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography. Int. J. Cardiovasc. Imaging 35(5), 759–760 (2019).
- 25. . 2018 ACC/HRS/NASCI/SCAI/SCCT expert consensus document on optimal use of ionizing radiation in cardiovascular imaging: best practices for safety and effectiveness – a review for the cardiac anesthesiologist. J. Cardiothorac. Vasc. Anesth. 33(11), 2902–2908 (2019).
- 26. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl. Sci. 3(4), 563–572 (2018).
- 27. . How to prevent and manage radiation-induced coronary artery disease. Heart 104(20), 1647–1653 (2018).
- 28. . Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br. Heart J. 69(6), 496–500 (1993).
- 29. . Coronary angioplasty of radiation-induced stenosis. Am. Heart J. 125(4), 1164–1166 (1993).
- 30. . Clinical and angiographic features of coronary artery disease after chest irradiation. Am. J. Cardiol. 60(13), 1020–1024 (1987).
- 31. . Radiation-induced coronary artery disease in young patients. Heart Views 19(1), 23–26 (2018).
- 32. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc. Interv. 79(3), 453–495 (2012).
- 33. . Cardiac complications of radiation therapy. Clin. Oncol. (R. Coll. Radiol.) 17(3), 153–159 (2005).
- 34. . Radiation-induced coronary artery disease and its treatment: a quick review of current evidence. Cardiol. Res. Pract. 2018, 8367268 (2018). •• These publications furnish a detailed perspective for cardio-oncology and cardiology professionals, framing the management challenges and strategies against the backdrop of a modern understanding of radiation therapy’s impact on cardiac health. They underscore the need to navigate patient care with a nuanced appreciation of the potential or actual cardiac complications arising from such treatments.
- 35. Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 76(3), 656–665 (2010).
- 36. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 38(7), 706 (2020).
- 37. Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617. Int. J. Radiat. Oncol. Biol. Phys. 117(5), 1270–1286 (2023).
- 38. . Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 980–987 (2009).
- 39. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005. Radiother. Oncol. 123(2), 299–305 (2017).
- 40. . Contemporary breast radiotherapy and cardiac toxicity. Semin. Radiat. Oncol. 26(1), 71–78 (2016).
- 41. Use of normal tissue complication probability models in the clinic. Int. J. Radiat. Oncol. Biol. Phys. 76(Suppl. 3), S10–S19 (2010).
- 42. . Radiation induced coronary artery disease. In: StatPearls. StatPearls Publishing, FL, USA (2022).
- 43. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34(38), 2949–3003 (2013).
- 44. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42(34), 3227–3337 (2021).
- 45. . Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells. Oncotarget 8(13), 20842–20850 (2017).
- 46. . Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells. J. Cell. Physiol. 233(1), 186–200 (2018).
- 47. . Prophylactic use of colchicine in preventing radiation induced coronary artery disease. Med. Hypotheses 111, 58–60 (2018).
- 48. . Coronary artery disease following mediastinal radiation therapy. J. Thorac. Cardiovasc. Surg. 85(2), 257–263 (1983).
- 49. . Surgical management of radiation-induced heart disease. Ann. Thorac. Surg. 65(4), 1014–1019 (1998).
- 50. . Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc. Interv. 70(3), 359–365 (2007).
- 51. . Myocarditis with immune checkpoint blockade. N. Engl. J. Med. 376(3), 291–292 (2017).
- 52. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375(18), 1749–1755 (2016).
- 53. . T cell checkpoint regulators in the heart. Cardiovasc. Res. 115(5), 869–877 (2019).
- 54. . Cardiovascular toxicities associated with immune checkpoint inhibitors. Zhonghua Zhong Liu Za Zhi 42(7), 609–613 (2020).
- 55. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116(18), 2062–2071 (2007).
- 56. . Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317–325 (2011).
- 57. . Targeting the immune system in atherosclerosis: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73(13), 1691–1706 (2019).
- 58. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 31(5), 1100–1107 (2011).
- 59. . Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol. 174(22), 3940–3955 (2017).
- 60. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 29(1), 284–286 (2018). •• These studies highlight the risk of acute coronary syndrome associated with the use of nivolumab, prompting a valid concern that prior or concurrent use of nivolumab following thoracic radiotherapy may precipitate the early onset of radiation-induced coronary artery disease. Hence, as cancer therapies evolve, it is imperative that our comprehension of their potential cardiovascular impacts advances accordingly.
- 61. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can. J. Cardiol. 36(4), 476–481 (2020). •• These studies highlight the risk of acute coronary syndrome associated with the use of nivolumab, prompting a valid concern that prior or concurrent use of nivolumab following thoracic radiotherapy may precipitate the early onset of radiation-induced coronary artery disease. Hence, as cancer therapies evolve, it is imperative that our comprehension of their potential cardiovascular impacts advances accordingly.
- 62. . Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy. Front. Oncol. 12, 1025455 (2022).
- 63. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation 142(24), 2396–2398 (2020).
- 64. . Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc. Pathol. 43, 107148 (2019).
- 65. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142(24), 2299–2311 (2020).
- 66. . Early onset acute coronary artery occlusion after pembrolizumab in advanced non-small cell lung cancer: a case report. Cardiovasc. Toxicol. 21(8), 683–686 (2021).
- 67. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377(20), 1919–1929 (2017).
- 68. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 7(9), 1–9 (2021).